About Cernostics

Cernostics is a leader in tissue-based diagnostic testing, providing assays with deeper tissue insights, better patient outcomes, and lower cost of care. The Cernostics laboratory is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and is qualified to perform high-complexity clinical testing (CLIA#: 39D2110302). The TissueCypher® Barrett’s Esophagus Assay is used for clinical purposes and should not be regarded as investigational or for research.

Cernostics Contact Information
Email: Customer.service@cernostics.com
Call: 412-820-3050
For Additional Information about Cernostics, Inc. or TissueCypher® technology, please go to: www.Cernostics.com

Improving Care for Patients with Barrett’s Esophagus

TissueCypher® provides increased confidence that treatment decisions are tailored to each individual patient, leading to more personalized and precise care.
What is the TissueCypher® Barrett’s Esophagus Assay?

The TissueCypher® Barrett’s Esophagus Assay is the first diagnostic test of its kind that predicts your risk for developing esophageal cancer if you have Barrett’s Esophagus. It is intended for people with Barrett’s esophagus who have had an endoscopy procedure with biopsies. The assay analyzes the biopsies taken during your endoscopy to produce a risk score that ranges from 0-10, with 0 being the lowest risk and 10 being the highest risk for developing esophageal cancer. More importantly, the assay provides personalized information that can estimate your chances for developing cancer, which is not available through other tests.

What are the potential benefits of this test?

TissueCypher® provides increased confidence that treatment decisions are tailored to each individual patient, leading to more personalized and precise care.

- Test can be performed on existing biopsies taken during previous endoscopies; a repeat biopsy is NOT necessary.
- Identifies patients at high risk of progression to esophageal cancer within five years of biopsy
- Helps detect existing high risk disease or cancer that might have been missed by standard endoscopic surveillance
- Identifies patients who have a very low risk of progressing to cancer within 5 years of biopsy
- Outperforms predictions based on standard pathology alone
- Turnaround Time: 14 Days

Will my insurance cover this test?

The TissueCypher® Barrett’s Esophagus Assay will be covered by most insurance plans. Cernostics is committed to providing Barrett’s Esophagus patients with access to TissueCypher® regardless of their personal financial situation.

- TissueCypher® technology uses medical testing procedures commonly covered by all health insurance providers including Medicare
- Cernostics will bill Medicare or private health insurance on your behalf, or may work with your provider’s clinical laboratory that will bill your insurance for the test
- Patients will be responsible for co-pays and deductibles. Generous financial assistance programs are available for those patients who qualify.
- For patients denied insurance coverage, or without health insurance, Cernostics has “patient responsibility pricing” and a Financial Assistance Program to help patients access TissueCypher testing. Please directly inquire using the Cernostics Contact Information on the back page.

When is it used?

The TissueCypher® Barrett’s Esophagus Assay can be used after you have had an endoscopy with biopsies that have been confirmed by a pathologist to contain Barrett’s Esophagus. Test results are reported directly to your doctor approximately 14 days from the date your sample is received by Cernostics.